Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.
Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.
复制标题
恶性乳腺肿瘤中 Her-2/neu 和 INT2 原癌基因扩增与生殖因素和外源激素暴露的关系。
DOI：
--
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
H. Sigurdsson
中科院分区：
文献类型：
--
作者：
H. Olsson;Å. Borg;M. Fernö;J. Ranstam;H. Sigurdsson
在瑞典南部先前的研究中，发现早期使用口服避孕药会增加患绝经前乳腺癌的风险，并且这些患者的肿瘤表现出更具攻击性的行为。在本研究中，我们研究了72例绝经前妇女原发肿瘤标本中原癌基因Her-2/neu（也称为ERBB2）和INT2的扩增，它们与口服避孕药起始年龄和其他生殖危险因素有关。Her-2/neu扩增在早期口服避孕药使用者（即年龄小于或等于20岁的口服避孕药使用者）中比在不使用或晚期使用避孕药者中更为常见（优势比[or]， 5.3； 95%可信区间[CI]， 1.6-16.7），而INT2扩增在两组间无显著差异（or, 0.9; 95% CI, 0.1-5.0）。在使用黄体酮和首次足月妊娠前有流产史的患者中，INT2扩增的可能性更大（分别为OR， 9.0; 95% CI, 1.3-51.7； OR, 18.6; 95% CI, 2.2-165.8）。未发现原癌基因扩增与胎次、首次足月妊娠年龄或晚期流产等变量之间存在显著关系。在调整了诊断年龄和其他危险因素后，ORs的增加仍然存在。研究结果表明，早期口服避孕药使用者Her-2/ new扩增率较高是口服避孕药使用本身的影响，而不是使用者相对年轻的影响。此外，使用黄体酮与早期流产和INT2基因扩增之间的关系在生物学上是合理的。
In previous studies in southern Sweden, early use of oral contraceptives has been found to be accompanied by an increased risk of developing premenopausal breast cancer, and the tumors developing in these patients have shown a more aggressive behavior. In the present study, amplification of the proto-oncogenes Her-2/neu (also known as ERBB2) and INT2 was studied in primary tumor specimens from 72 premenopausal women and was related to starting age of oral contraceptive use and other reproductive risk factors. Amplification of Her-2/neu was more common among early oral contraceptive users (i.e., those starting at less than or equal to 20 years of age) than among nonusers or late users (odds ratio [OR], 5.3; 95% confidence interval [CI], 1.6-16.7), whereas INT2 amplification did not differ significantly among those groups (OR, 0.9; 95% CI, 0.1-5.0). The likelihood of INT2 amplification was greater among users of progestins and those with a history of abortions before the first full-term pregnancy (OR, 9.0; 95% CI, 1.3-51.7; and OR, 18.6; 95% CI, 2.2-165.8, respectively). No significant relationships were found between proto-oncogene amplification and the variables of parity, age at first full-term pregnancy, or late abortion. The increased ORs persisted after adjustment for age at diagnosis and other risk factors. The findings suggest that the higher rate of Her-2/neu amplification among early oral contraceptive users is an effect of the oral contraceptive use per se rather than of the relative youth of the users. Moreover, the relationship between progestin use and early abortion and amplification of the INT2 gene is biologically plausible.